Inclusion criteria were EFWD 20% before 27 weeks and adequate ultrasound (US) information to assess for interval growth until delivery, defined as last US within 5 weeks of delivery. We excluded those with major structural anomalies, pregnancies that were terminated, those that developed twin-twin transfusion syndrome, and those that developed polyhydramnios. The primary outcome was development of sFGR in the smaller twin, defined as estimated fetal weight 10th percentile for gestational age (GA). Predictors included maternal demographics (age, nulliparity, and use of assisted reproductive technology), US findings (cord insertion of smaller twin and presence of arterio-arterial anastomosis), and details at time of EFWD diagnosis (GA at diagnosis and degree of EFWD). The Kruskal-Wallis test generated median values for non-parametric continuous variables, and Fisher's exact tests compared proportions between categorical variables. RESULTS: A total of 38 MCDA pairs met the inclusion criteria, with 26 (68%) developing sFGR at a median GA of 23.9 weeks (20.7-35.1). There were no statistically significant differences in maternal demographics, US findings, or GA at time of EFWD diagnosis comparing those who developed sFGR and those who did not. OBJECTIVE: To demonstrate the utility of non-invasive prenatal screening for single-gene disorders (NIPT-SGD) in screening for skeletal dysplasia (SD) cases and in narrowing the differential diagnosis by ultrasound STUDY DESIGN: SDs are a group of disorders that affect the development of bone/connective tissue. Determining a specific diagnosis when a SD is suspected by ultrasound is challenging due to the wide phenotypic spectrum and overlapping features. Genetic counseling and perinatal decision-making, however, may differ when a specific diagnosis is established. NIPT-SGD screens for mutations in 30 genes by analysis of cell-free DNA from maternal plasma and maternal/paternal genomic DNA using next-generation sequencing. Results of NIPT-SGD were compared with the leading diagnosis based on ultrasound for two clinical cases. RESULTS: Case 1 A 26-year-old G3P2 was referred at 19 weeks for an anatomy ultrasound; long bone lengths were below the 5 th percentile and achondrogenesis type 2 was suspected. The father of the baby was identified as a carrier for hypophosphatasia, severe forms of which are inherited in an autosomal recessive manner and is interpreted as a severe SD in utero. The patient received a negative carrier screening test result for hypophosphatasia. NIPT-SGD identified a likely pathogenic mutation in COL1A2, consistent with osteogenesis imperfecta (OI), which was confirmed by amniocentesis.
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Case 2 A 22-year-old G1 was referred for ultrasound at 29 weeks due to long bone shortening; long bone lengths were below the 3 rd percentile. The findings were interpreted as consistent with achondroplasia with "no findings to suggest a lethal form of dwarfism". NIPT-SGD identified a pathogenic mutation in COL1A2 consistent with OI. The baby was delivered by cesarean section and a femoral fracture was noted at birth. CONCLUSION: These cases demonstrate the complexity of prenatal diagnosis of SDs based on ultrasound findings alone. In both cases, the "leading" diagnosis based on ultrasound findings was discordant from results of NIPT-SGD. Establishment of a diagnosis of OI has significant implications for perinatal management. NIPT-SGD provides a non-invasive method of refining the diagnosis when a SD is suspected by ultrasound. OBJECTIVE: Current guidelines advise against using multiple modalities for aneuploidy screening. We investigated the additional benefit as well as the healthcare burden of 1 st and 2 nd trimester serum analyte screening in women with normal NIPT results. STUDY DESIGN: This is a retrospective cohort study of singleton pregnancies delivered at UCSF between 2013 and 2017. Women were included if they had both NIPT and serum analyte screening and NIPT results were normal. Serum analytes were considered abnormal if PAPP-A0.29 MoM, AFP2.5 MoM, hCG3 MoM, estriol0.1 MoM, or inhibin3 MoM. If there were two or more abnormal analytes the cutoffs were PAPP-A 0.29, AFP2 MoM, hCG2 MoM, estriol 0.2 MoM, or inhibin2 MoM. Those with normal analytes were compared to those with abnormal analytes for risk of an adverse perinatal outcome, defined as any of the following: preterm delivery, SGA, NICU admission, IUFD, or 5-minute Apgar <5. We also examined utilization of health care resources between groups. RESULTS: Of the 2,331 women who met inclusion criteria, 228 (9.8%) had abnormal analytes. Women of Asian or Pacific Islander origins were proportionally more common in the abnormal analytes group; sociodemographic, medical, and prior pregnancy characteristics were otherwise similar. Overall, adverse perinatal outcomes were more common in those with abnormal analytes (37.3% vs. 25.0%, p<0.001), including preterm birth, cesarean delivery, preeclampsia and small for gestational age neonates. Controlling for possible confounders, abnormal analytes were independently 
